Key result
IonWorks Quattro assays provide reliable pharmacological profiling for cardiac ion channel liability.
Why the study?
Preclinical profiling for off-target cardiac ion channel interactions is essential to assess cardiac liability and reduce clinical arrhythmia risk during drug discovery.
Population
Three cardiac ion channels (hKCNQ1/minK, hCa(v)1.2, and hNa(v)1.5)
Comparison
Assay development on the IonWorks Quattro automated patch clamp system
Design
Preclinical assay development study
Authors
Loading...
Supports targeted LQTS genetic testing; leaves open functional validation of variants for therapy development.
The IonWorks Quattro system provides reliable automated patch clamp assays for preclinical profiling of cardiac ion channel inhibition to assess drug-induced arrhythmia liability.
Cao et al. (2010) studied Cardiac arrhythmia risk / Preclinical safety profiling. IonWorks Quattro automated patch clamp system assays was evaluated on Assay development for three cardiac ion channels (hKCNQ1/minK, hCa(v)1.2, and hNa(v)1.5). Assays developed for three cardiac ion channels (hKCNQ1/minK, hCa(v)1.2, and hNa(v)1.5) on the IonWorks Quattro system can be used as reliable pharmacological profiling tools for cardiac liability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: